Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Emerging Views On Emerging Markets: JP Morgan Healthcare Conference (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

Emerging markets continued to play a large role in company presentations during the industry’s largest investor conference. PharmAsia News takes a closer look.

You may also be interested in...

Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So

SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt

Emerging Views On Emerging Markets: Bank of America Merrill Lynch Global Healthcare Conference

In this periodic feature, PharmAsia News listens in at major industry events to hear what senior executives have to say about Asia and other emerging markets. In our last profile, we sat in on the recent Morgan Stanley Global Healthcare Conference in New York ('Emerging Views On Emerging Markets: Morgan Stanley Global Healthcare Conference,' PharmAsia News, Sept. 22, 2011). For this profile, we zoom in on the Bank of America Merrill Lynch Global Healthcare Conference, held Sept. 15-16 in London.

Medtronic Growth Plan: Boost R&D Productivity, Globalization

Medtronic's growth acceleration plan calls for optimizing its research and development investments, accelerating globalization efforts, and improving execution of all initiatives, according to newly installed CEO Omar Ishrak

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts